evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract,articles/13/pmid,articles/13/title,articles/13/journal,articles/13/pubDate,articles/13/volume,articles/13/issue,articles/13/pages,articles/13/authors,articles/13/elocationId,articles/13/link,articles/13/reference,articles/13/abstract,articles/14/pmid,articles/14/title,articles/14/journal,articles/14/pubDate,articles/14/volume,articles/14/issue,articles/14/pages,articles/14/authors,articles/14/elocationId,articles/14/link,articles/14/reference,articles/14/abstract,articles/15/pmid,articles/15/title,articles/15/journal,articles/15/pubDate,articles/15/volume,articles/15/issue,articles/15/pages,articles/15/authors,articles/15/elocationId,articles/15/link,articles/15/reference,articles/15/abstract
10192,GENE_BACKGROUND,,"EZH2 is the catalytic component of the Polycomb repressive complex 2 (PRC2) which is responsible for transcriptional repression by catalyzing di- and tri-methylation of Histone H3 lysine 27 (H3K27). EZH2 requires other members of the PRC2 complex for full methyltransferase activity, including SUZ12 and EED (PMID: 15225548, 15916951), and PRC2 function is important in repression of developmental regulators such as the HOX genes, and X-inactivation (PMID: 16618801, 12649488). Additionally, non-coding RNA's can guide EZH2 to genomic targets for gene repression (PMID: 17604720, 22659877). EZH2 overexpression is found in many malignancies including lymphoma, bladder cancer, melanoma, prostate cancer, lung cancer, and breast cancer, and is associated with advanced stage and poor prognosis (PMID: 11389032, 16361539, 12374981, 14500907, 16330673, 24097870). Furthermore, gain-of-function mutations in EZH2 occur frequently in follicular lymphoma and diffuse large B-cell lymphomas (PMID: 20081860, 21190999). EZH2 can also act as a tumor suppressor in certain cancer types, and recurrent inactivating mutations are observed in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) (PMID: 20601953). Given its importance in multiple cancer types, EZH2 inhibition has shown promise in pre-clinical studies and is a current effort in multiple clinical trials, either through direct inhibition of EZH2 enzymatic activity or through disruption in PRC2 stability (PMID: 26845405).",,2017-10-18,,2146,EZH2,enhancer of zeste 2 polycomb repressive complex 2 subunit,True,ENST00000320356,NM_004456.4,ENX-1,ENX1,EZH2b,WVS,WVS2,KMT6,KMT6A,False,11389032,Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma.,Blood,2018-06-15T20:01:00,97,12,3896-901,van Kemenade FJ et al,,,2018-06-15T09:01:00,,15225548,SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.,Molecular cell,2018-07-02T20:04:00,15,True,57-67,Cao R et al,,,0001-07-02,,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,Nature genetics,2018-08-01T20:10:00,42,8,722-6,Ernst T et al,doi: 10.1038/ng.621,,0001-08-01,,24097870,"EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.",Clinical cancer research : an official journal of the American Association for Cancer Research,2017-12-01T20:13:00,19,23,6556-65,Behrens C et al,doi: 10.1158/1078-0432.CCR-12-3946,,0001-12-01,,12649488,Role of histone H3 lysine 27 methylation in X inactivation.,"Science (New York, N.Y.)",2018-04-04T20:03:00,300,5616,131-5,Plath K et al,,,0001-04-04,,15916951,The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation.,Current biology : CB,2018-05-24T20:05:00,15,10,942-7,Montgomery ND et al,,,0001-05-24,,17604720,Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs.,Cell,2018-06-29T20:07:00,129,7,1311-23,Rinn JL et al,,,0001-06-29,,16361539,"Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.",Clinical cancer research : an official journal of the American Association for Cancer Research,2017-12-15T20:05:00,11,24 Pt 1,8570-6,Raman JD et al,,,0001-12-15,,20081860,Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.,Nature genetics,2018-02-01T20:10:00,42,2,181-5,Morin RD et al,doi: 10.1038/ng.518,,0001-02-01,,21190999,"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",Blood,2018-02-24T20:11:00,117,8,2451-9,Yap DB et al,doi: 10.1182/blood-2010-11-321208,,0001-02-24,,26845405,Targeting EZH2 in cancer.,Nature medicine,2018-02-01T20:16:00,22,2,128-34,Kim KH et al,doi: 10.1038/nm.4036,,0001-02-01,,16618801,Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.,Genes &amp; development,2018-05-01T20:06:00,20,9,1123-36,Bracken AP et al,,,0001-05-01,,14500907,EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.,Proceedings of the National Academy of Sciences of the United States of America,2018-09-30T20:03:00,100,20,11606-11,Kleer CG et al,,,0001-09-30,,16330673,"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2018-01-10T20:06:00,24,2,268-73,Bachmann IM et al,,,0001-01-10,,22659877,Intronic RNAs mediate EZH2 regulation of epigenetic targets.,Nature structural &amp; molecular biology,2018-06-03T20:12:00,19,7,664-70,Guil S et al,doi: 10.1038/nsmb.2315,,0001-06-03,,12374981,The polycomb group protein EZH2 is involved in progression of prostate cancer.,Nature,2018-10-10T20:02:00,419,6907,624-9,Varambally S et al,,,0001-10-10,
10191,GENE_SUMMARY,,"EZH2, an epigenetic modifier, is altered by mutation and/or overexpression in solid tumors and hematological malignancies.",,2017-04-03,,2146,EZH2,enhancer of zeste 2 polycomb repressive complex 2 subunit,True,ENST00000320356,NM_004456.4,ENX-1,ENX1,EZH2b,WVS,WVS2,KMT6,KMT6A,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
